{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:36:02Z","timestamp":1792427762061,"version":"4.5.0"},"reference-count":42,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,11,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The objective of this phase II trial was to assess the efficacy and toxicity of weekly paclitaxel for patients with metastatic or unresectable angiosarcoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Thirty patients were entered onto the study from April 2005 through October 2006. Paclitaxel was administered intravenously as a 60-minute infusion at a dose of 80 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on days 1, 8, and 15 of a 4-week cycle. The primary end point was the nonprogression rate after two cycles.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The progression-free survival rates after 2 and 4 months were 74% and 45%, respectively. With a median follow-up of 8 months, the median time to progression was 4 months and the median overall survival was 8 months. The progression-free survival rate was similar in patients pretreated with chemotherapy and in chemotherapy-na\u00efve patients (77% v 71%). Three patients with locally advanced breast angiosarcoma presented partial response, which enabled a secondary curative-intent surgery with complete histologic response in two cases. One toxic death occurred as a result of a thrombocytopenia episode. Six patients presented with grade 3 toxicities and one patient presented with a grade 4 toxicity. Anemia and fatigue were the most frequently reported toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Weekly paclitaxel at the dose schedule used in the current study was well tolerated and demonstrated clinical benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2008.17.3146","type":"journal-article","created":{"date-parts":[[2008,9,22]],"date-time":"2008-09-22T20:14:30Z","timestamp":1222114470000},"page":"5269-5274","source":"Crossref","is-referenced-by-count":597,"title":["Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study"],"prefix":"10.1200","volume":"26","author":[{"given":"Nicolas","family":"Penel","sequence":"first","affiliation":[{"name":"From the D\u00e9partement de Canc\u00e9rologie G\u00e9n\u00e9rale, Unit\u00e9 de Biostatistiques, and D\u00e9partement d\u2019Imagerie M\u00e9dicale, Centre Oscar Lambret; Equipe d\u2019Accueil 2694, Sant\u00e9 Publique, Epid\u00e9miologie et mod\u00e9lisation des maladies chroniques, Universit\u00e9 Lille II, Lille; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Bergoni\u00e9, Bordeaux; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Jean Perrin, Clermont-Ferrand; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Val d\u2019Aurelle, Montpellier; D\u00e9partement d\u2019Oncologie M\u00e9dicale, and Unit\u00e9..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binh Nguyen","family":"Bui","sequence":"additional","affiliation":[{"name":"From the D\u00e9partement de Canc\u00e9rologie G\u00e9n\u00e9rale, Unit\u00e9 de Biostatistiques, and D\u00e9partement d\u2019Imagerie M\u00e9dicale, Centre Oscar Lambret; Equipe d\u2019Accueil 2694, Sant\u00e9 Publique, Epid\u00e9miologie et mod\u00e9lisation des maladies chroniques, Universit\u00e9 Lille II, Lille; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Bergoni\u00e9, Bordeaux; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Jean Perrin, Clermont-Ferrand; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Val d\u2019Aurelle, Montpellier; D\u00e9partement d\u2019Oncologie M\u00e9dicale, and Unit\u00e9..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Olivier","family":"Bay","sequence":"additional","affiliation":[{"name":"From the D\u00e9partement de Canc\u00e9rologie G\u00e9n\u00e9rale, Unit\u00e9 de Biostatistiques, and D\u00e9partement d\u2019Imagerie M\u00e9dicale, Centre Oscar Lambret; Equipe d\u2019Accueil 2694, Sant\u00e9 Publique, Epid\u00e9miologie et mod\u00e9lisation des maladies chroniques, Universit\u00e9 Lille II, Lille; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Bergoni\u00e9, Bordeaux; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Jean Perrin, Clermont-Ferrand; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Val d\u2019Aurelle, Montpellier; D\u00e9partement d\u2019Oncologie M\u00e9dicale, and Unit\u00e9..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Cupissol","sequence":"additional","affiliation":[{"name":"From the D\u00e9partement de Canc\u00e9rologie G\u00e9n\u00e9rale, Unit\u00e9 de Biostatistiques, and D\u00e9partement d\u2019Imagerie M\u00e9dicale, Centre Oscar Lambret; Equipe d\u2019Accueil 2694, Sant\u00e9 Publique, Epid\u00e9miologie et mod\u00e9lisation des maladies chroniques, Universit\u00e9 Lille II, Lille; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Bergoni\u00e9, Bordeaux; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Jean Perrin, Clermont-Ferrand; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Val d\u2019Aurelle, Montpellier; D\u00e9partement d\u2019Oncologie M\u00e9dicale, and Unit\u00e9..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[{"name":"From the D\u00e9partement de Canc\u00e9rologie G\u00e9n\u00e9rale, Unit\u00e9 de Biostatistiques, and D\u00e9partement d\u2019Imagerie M\u00e9dicale, Centre Oscar Lambret; Equipe d\u2019Accueil 2694, Sant\u00e9 Publique, Epid\u00e9miologie et mod\u00e9lisation des maladies chroniques, Universit\u00e9 Lille II, Lille; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Bergoni\u00e9, Bordeaux; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Jean Perrin, Clermont-Ferrand; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Val d\u2019Aurelle, Montpellier; D\u00e9partement d\u2019Oncologie M\u00e9dicale, and Unit\u00e9..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Piperno-Neumann","sequence":"additional","affiliation":[{"name":"From the D\u00e9partement de Canc\u00e9rologie G\u00e9n\u00e9rale, Unit\u00e9 de Biostatistiques, and D\u00e9partement d\u2019Imagerie M\u00e9dicale, Centre Oscar Lambret; Equipe d\u2019Accueil 2694, Sant\u00e9 Publique, Epid\u00e9miologie et mod\u00e9lisation des maladies chroniques, Universit\u00e9 Lille II, Lille; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Bergoni\u00e9, Bordeaux; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Jean Perrin, Clermont-Ferrand; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Val d\u2019Aurelle, Montpellier; D\u00e9partement d\u2019Oncologie M\u00e9dicale, and Unit\u00e9..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Kerbrat","sequence":"additional","affiliation":[{"name":"From the D\u00e9partement de Canc\u00e9rologie G\u00e9n\u00e9rale, Unit\u00e9 de Biostatistiques, and D\u00e9partement d\u2019Imagerie M\u00e9dicale, Centre Oscar Lambret; Equipe d\u2019Accueil 2694, Sant\u00e9 Publique, Epid\u00e9miologie et mod\u00e9lisation des maladies chroniques, Universit\u00e9 Lille II, Lille; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Bergoni\u00e9, Bordeaux; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Jean Perrin, Clermont-Ferrand; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Val d\u2019Aurelle, Montpellier; D\u00e9partement d\u2019Oncologie M\u00e9dicale, and Unit\u00e9..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Fournier","sequence":"additional","affiliation":[{"name":"From the D\u00e9partement de Canc\u00e9rologie G\u00e9n\u00e9rale, Unit\u00e9 de Biostatistiques, and D\u00e9partement d\u2019Imagerie M\u00e9dicale, Centre Oscar Lambret; Equipe d\u2019Accueil 2694, Sant\u00e9 Publique, Epid\u00e9miologie et mod\u00e9lisation des maladies chroniques, Universit\u00e9 Lille II, Lille; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Bergoni\u00e9, Bordeaux; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Jean Perrin, Clermont-Ferrand; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Val d\u2019Aurelle, Montpellier; D\u00e9partement d\u2019Oncologie M\u00e9dicale, and Unit\u00e9..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Taieb","sequence":"additional","affiliation":[{"name":"From the D\u00e9partement de Canc\u00e9rologie G\u00e9n\u00e9rale, Unit\u00e9 de Biostatistiques, and D\u00e9partement d\u2019Imagerie M\u00e9dicale, Centre Oscar Lambret; Equipe d\u2019Accueil 2694, Sant\u00e9 Publique, Epid\u00e9miologie et mod\u00e9lisation des maladies chroniques, Universit\u00e9 Lille II, Lille; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Bergoni\u00e9, Bordeaux; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Jean Perrin, Clermont-Ferrand; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Val d\u2019Aurelle, Montpellier; D\u00e9partement d\u2019Oncologie M\u00e9dicale, and Unit\u00e9..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Jimenez","sequence":"additional","affiliation":[{"name":"From the D\u00e9partement de Canc\u00e9rologie G\u00e9n\u00e9rale, Unit\u00e9 de Biostatistiques, and D\u00e9partement d\u2019Imagerie M\u00e9dicale, Centre Oscar Lambret; Equipe d\u2019Accueil 2694, Sant\u00e9 Publique, Epid\u00e9miologie et mod\u00e9lisation des maladies chroniques, Universit\u00e9 Lille II, Lille; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Bergoni\u00e9, Bordeaux; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Jean Perrin, Clermont-Ferrand; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Val d\u2019Aurelle, Montpellier; D\u00e9partement d\u2019Oncologie M\u00e9dicale, and Unit\u00e9..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Isambert","sequence":"additional","affiliation":[{"name":"From the D\u00e9partement de Canc\u00e9rologie G\u00e9n\u00e9rale, Unit\u00e9 de Biostatistiques, and D\u00e9partement d\u2019Imagerie M\u00e9dicale, Centre Oscar Lambret; Equipe d\u2019Accueil 2694, Sant\u00e9 Publique, Epid\u00e9miologie et mod\u00e9lisation des maladies chroniques, Universit\u00e9 Lille II, Lille; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Bergoni\u00e9, Bordeaux; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Jean Perrin, Clermont-Ferrand; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Val d\u2019Aurelle, Montpellier; D\u00e9partement d\u2019Oncologie M\u00e9dicale, and Unit\u00e9..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Peyrade","sequence":"additional","affiliation":[{"name":"From the D\u00e9partement de Canc\u00e9rologie G\u00e9n\u00e9rale, Unit\u00e9 de Biostatistiques, and D\u00e9partement d\u2019Imagerie M\u00e9dicale, Centre Oscar Lambret; Equipe d\u2019Accueil 2694, Sant\u00e9 Publique, Epid\u00e9miologie et mod\u00e9lisation des maladies chroniques, Universit\u00e9 Lille II, Lille; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Bergoni\u00e9, Bordeaux; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Jean Perrin, Clermont-Ferrand; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Val d\u2019Aurelle, Montpellier; D\u00e9partement d\u2019Oncologie M\u00e9dicale, and Unit\u00e9..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chevreau","sequence":"additional","affiliation":[{"name":"From the D\u00e9partement de Canc\u00e9rologie G\u00e9n\u00e9rale, Unit\u00e9 de Biostatistiques, and D\u00e9partement d\u2019Imagerie M\u00e9dicale, Centre Oscar Lambret; Equipe d\u2019Accueil 2694, Sant\u00e9 Publique, Epid\u00e9miologie et mod\u00e9lisation des maladies chroniques, Universit\u00e9 Lille II, Lille; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Bergoni\u00e9, Bordeaux; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Jean Perrin, Clermont-Ferrand; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Val d\u2019Aurelle, Montpellier; D\u00e9partement d\u2019Oncologie M\u00e9dicale, and Unit\u00e9..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Bompas","sequence":"additional","affiliation":[{"name":"From the D\u00e9partement de Canc\u00e9rologie G\u00e9n\u00e9rale, Unit\u00e9 de Biostatistiques, and D\u00e9partement d\u2019Imagerie M\u00e9dicale, Centre Oscar Lambret; Equipe d\u2019Accueil 2694, Sant\u00e9 Publique, Epid\u00e9miologie et mod\u00e9lisation des maladies chroniques, Universit\u00e9 Lille II, Lille; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Bergoni\u00e9, Bordeaux; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Jean Perrin, Clermont-Ferrand; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Val d\u2019Aurelle, Montpellier; D\u00e9partement d\u2019Oncologie M\u00e9dicale, and Unit\u00e9..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne G.C.","family":"Brain","sequence":"additional","affiliation":[{"name":"From the D\u00e9partement de Canc\u00e9rologie G\u00e9n\u00e9rale, Unit\u00e9 de Biostatistiques, and D\u00e9partement d\u2019Imagerie M\u00e9dicale, Centre Oscar Lambret; Equipe d\u2019Accueil 2694, Sant\u00e9 Publique, Epid\u00e9miologie et mod\u00e9lisation des maladies chroniques, Universit\u00e9 Lille II, Lille; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Bergoni\u00e9, Bordeaux; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Jean Perrin, Clermont-Ferrand; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Val d\u2019Aurelle, Montpellier; D\u00e9partement d\u2019Oncologie M\u00e9dicale, and Unit\u00e9..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[{"name":"From the D\u00e9partement de Canc\u00e9rologie G\u00e9n\u00e9rale, Unit\u00e9 de Biostatistiques, and D\u00e9partement d\u2019Imagerie M\u00e9dicale, Centre Oscar Lambret; Equipe d\u2019Accueil 2694, Sant\u00e9 Publique, Epid\u00e9miologie et mod\u00e9lisation des maladies chroniques, Universit\u00e9 Lille II, Lille; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Institut Bergoni\u00e9, Bordeaux; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Jean Perrin, Clermont-Ferrand; D\u00e9partement d\u2019Oncologie M\u00e9dicale, Centre Val d\u2019Aurelle, Montpellier; D\u00e9partement d\u2019Oncologie M\u00e9dicale, and Unit\u00e9..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870301)59:5<1046::AID-CNCR2820590533>3.0.CO;2-6"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.0.CO;2-P"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9098(200003)73:3<182::AID-JSO14>3.0.CO;2-N"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-Z"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.017"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.080"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870815)60:4<777::AID-CNCR2820600412>3.0.CO;2-T"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1975.tb51097.x"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10634"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg461"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.20.9552"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1007\/BF02592403"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504133321507"},{"key":"R15","unstructured":"Seidman AD: The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 1:247,1995-256,"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2654"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.130"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11375"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-006-0642-x"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1080\/02841860600833178"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199710000-00002"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.3109\/07357909809011697"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21140"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.7261"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000224453.39200.d7"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2624"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20595"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-10-833"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.150"},{"key":"R33","unstructured":"Borden EC, Baker LH, Bell RS, et al: Soft tissue sarcomas of adults: State of the translational science. Clin Cancer Res 9:1941,2003-1956,"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041866"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70169-9"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.2443"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.098"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940515)73:10<2506::AID-CNCR2820731009>3.0.CO;2-S"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.050"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20544"},{"key":"R41","unstructured":"Gian VG, Johnson TJ, Marsh RW, et al: A phase II study of paclitaxel in the treatment of recurrent or metastatic soft tissue sarcomas or bone sarcomas. J Exp Ther Oncol 1:186,1996-190,"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951201)76:11<2248::AID-CNCR2820761111>3.0.CO;2-Y"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2008.17.3146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:24:36Z","timestamp":1653510276000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.17.3146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,10]]},"references-count":42,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2008,11,10]]}},"alternative-id":["10.1200\/JCO.2008.17.3146"],"URL":"https:\/\/doi.org\/10.1200\/jco.2008.17.3146","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,10]]}}}